GLPwatch
Tirzepatide
Approved · GIP and GLP-1 receptor dual agonist
Last updated 2026-08-07Tirzepatide is a dual-action drug that works by activating two natural hormones in the body, GIP and GLP-1, which help control blood sugar and appetite. It is sold under the brand names Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea.
AI summary of the sources below.
| Mechanism | GIP and GLP-1 receptor dual agonist Mimics two gut hormones, GIP and GLP-1, which together lower blood sugar and reduce appetite. |
|---|---|
| Status | Approved |
| Branded products | mounjaro, zepbound |
| Manufacturer(s) | eli-lilly |
How Tirzepatide connects
- Products MounjaroZepbound
- Treats Type 2 diabetesObesityObstructive sleep apnea
- Maker Eli Lilly
- Trials 181 trials
- Research 967 papers
Trials (181)
- A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
- Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction
- A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
- A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants
- A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)
- A Study of Weight Loss Intervention With Tirzepatide and Progestin Intrauterine Device to Treat Endometrial Hyperplasia and Grade 1 Endometrial Cancer
- The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
- Tirzepatide for the Treatment of Cannabis Use Disorder
- A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
- Efficacy, Safety, and Tolerability of Tirzepatide in Real-World Conditions in Paraguay.
- Tirzepatide and Muscle Outcomes in Obesity
- Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)
- A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- Study of Tirzepatide for Recovery and Alcohol Use Management
- A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease
- A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function
- A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
- CARTIZ Registry: Cartilage, Arthropathy and Imaging Under Tirzepatide in Zone-stratified Cohorts - A Four-Institute Mexican Observational Registry
- Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
- Tirzepatide Use in People With Obesity and Type 1 Diabetes
- Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
- Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
- Tirzepatide in the Treatment of Cannabis Use Disorder
- Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.
- Tirzepatide Weight Loss for MRD+ Early Breast Cancer
Top research (967)
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
- Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial.
- Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
- Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.
- Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.
- Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.
- Tirzepatide for Obesity Treatment and Diabetes Prevention.
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes.
- Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction.
- Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.
- Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes.
- Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial.
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity.
- Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial.
- Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis.
- GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice.